Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dragonfly Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Genmab
Akeso
Eastern Cooperative Oncology Group
City of Hope Medical Center
Eli Lilly and Company
University of Washington
Charite University, Berlin, Germany
National Cancer Institute (NCI)
Wake Forest University Health Sciences
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Anova Innovation Limited
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Astellas Pharma Inc
NRG Oncology
Jonsson Comprehensive Cancer Center
Mayo Clinic
Mayo Clinic
SWOG Cancer Research Network
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center